Concord Biotech Reports Strong Growth Amid Broader Market Decline

Concord Biotech, a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects the company's strong long-term fundamental strength, highlighted by an average Return on Equity (ROE) of 20.62%. The firm has demonstrated healthy growth, with operating profit increasing at an annual rate of 26.51%.
In its latest quarterly results for Q4 FY24-25, Concord Biotech reported net sales of Rs 429.88 crore, marking a growth of 57.9% compared to the previous four-quarter average. Additionally, the Profit After Tax (PAT) reached Rs 140.39 crore, showing a significant increase of 72.1%. The company's PBDIT also reached its highest level at Rs 190.42 crore during this period.

Despite the broader market, represented by the BSE500, experiencing negative returns of -2.34% over the past year, Concord Biotech has managed to generate returns of 9.98%. However, it is worth noting that institutional investors have slightly reduced their stake in the company, now holding 17.97%.

For more insights on Concord Biotech's performance and evaluation, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.